Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY231 in Relapsed or Refractory B-ALL
NCT06902025Phase 1Not yet recruiting
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JY231 in B cell acute lymphoblastic leukemia (B-ALL). Primary endpoints: Incidence of adverse events (AE) after infusion at Month 24 and Maximal Tolerated Dose. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
JY231
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06902025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902025.